[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617241":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":33,"slug":7,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Research Site","RECRUITING","Beijing","China","CN",{"type":22,"coordinates":23},"Point",[24,25],116.39723,39.9075,{"lat":25,"lon":24},[28],{"name":29,"role":11,"phone":7,"phoneExt":7,"email":30},"Shugeng Gao","gaoshugeng@cicams.ac.cn",{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100617241",false,"NCT07316062","A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China","A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China","MAP","Inclusion Criteria:\n\n* Stage I-III at initial NSCLC diagnosis\n* Aged ≥18 years at first diagnosis of NSCLC\n* Timeframe of NSCLC diagnosis:\n\nFor DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027\n\nExclusion Criteria:\n\n* NSCLC is not the primary cancer diagnosis\n* Patients with a recent history of other tumor or concurrent other tumor\n* Patients participating in interventional clinical trials at time of initial diagnosis\n* Patients with positive pregnancy status at the time of diagnosis","ALL","18 Years",{"count":43,"type":44},3000,"ESTIMATED","OBSERVATIONAL","This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.",[48],"Non-Small-Cell Lung",[50],"NSCLC, chart review","2026-06-10",{"date":53,"type":54},"2026-06-11","ACTUAL",{"date":56,"type":54},"2026-04-29",{"date":58,"type":44},"2029-04-30",{"name":5,"class":6},1]